Usher Syndrome, Types 1F and 3 (PCDH15 and CLRN1), 2 Variants
SMAD4 Germline Mutation Analysis
ADAMTS2 Gene Mutation Analysis
Leukemia/Lymphoma Immunophenotyping by Flow Cytometry, Blood
Hepatitis D Virus (HDV) Antibody, Total
West Nile Virus (WNV) Antibody, IgM
Dihydrocodeine, Urine
Monkeypox Virus DNA by PCR
PIK3CA Gene Mutation Analysis (Therascreen PIK3CA)
Primidone, Serum
LDS
Sign up
Log in
LDS
/
Medical Tests
/
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
All
Diseases
Overview
Clinical Utility
Interpretation
Reference Ranges
Methodology
Specimen Collection
Additional Testing
Turnaround Time
CPT
LOINC
ICD10
Additional ICD10
References
All
Diseases
Overview
Clinical Utility
Interpretation
Reference Ranges
Methodology
Specimen Collection
Additional Testing
Turnaround Time
CPT
LOINC
ICD10
Additional ICD10
References
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
Medical Test
Methodology
Access to
ABL1 Kinase Domain Mutation Analysis for Tyrosine Kinase Inhibitor Resistance in CML, NGS
is restricted.
Sign up now